Search

Displaying results 1921 - 1930 of 10000 in total
  1. Drug

    Momelotinib

    go.drugbank.com/drugs/DB11763
    ApprovedInvestigational

    It is a competitive inhibitor of JAK ATP binding.[A261566] First approved by the FDA on September 15, 2023,[L48206] momelotinib is used to treat myelofibrosis. … [L48186] Myelofibrosis (MF) is a group of myeloproliferative neoplasms characterized by abnormal proliferative hematopoietic stem cells, leading to the release of cytokines and growth factors.

  2. Drug

    Dolasetron

    go.drugbank.com/drugs/DB00757
    ApprovedInvestigational

    Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: Anzemet Injection 20 mg/ml
  3. Drug

    Ticarcillin

    go.drugbank.com/drugs/DB01607
    ApprovedVet approvedWithdrawn

    An antibiotic derived from penicillin similar to carbenicillin in action.

    Categories: combinations of penicillins
  4. Drug

    Lacidipine

    go.drugbank.com/drugs/DB09236
    Approved

    It is available as once-daily oral tablets containing 2 or 4 mg of the active compound commonly marketed as Lacipil or Motens. It is not currently FDA-approved. … In randomised, well-controlled trials, administration of daily single-dose lacidipine ranging from 2-6 mg demonstrated comparable antihypertensive efficacy similar to that of other long-acting dihydropyridine

    Products: LACIDIPINA EG, LACIPIL TABLET 4 mg
  5. Drug

    Pirtobrutinib

    go.drugbank.com/drugs/DB17472
    ApprovedInvestigational

    [A256788] In January 2023, the use of pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy was approved under the FDA's Accelerated … in the presence of Cys481 mutations.

  6. Drug

    Carbenicillin

    go.drugbank.com/drugs/DB00578
    Approved

    Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function.

    Categories: combinations of penicillins, Penicillin G
  7. Drug

    Moxonidine

    go.drugbank.com/drugs/DB09242
    ApprovedInvestigationalWithdrawn

    As well, moxonidine has been shown to present blood pressure-independent beneficial effects on insulin resistance syndrome. … Moxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild to moderate essential hypertension.

    Products: MOXONIDINA EG, Normohex 0,2 mg - Filmtabletten
  8. Drug

    Pizotifen

    go.drugbank.com/drugs/DB06153
    Approved

    Numerous studies have revealed the potential antidepressant effects of pizotifen, which are independent of its antimigraine action [A32538]. … Sandomigran is available in a number of countries but is not approved by the FDA nor EMA.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: Pizogran Tablet 0.5 mg, SANDOMIGRAN 0,5 MG KAPLI TABLET, 30 ADET
  9. Drug

    Procarbazine

    go.drugbank.com/drugs/DB01168
    ApprovedInvestigational

    An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  10. Drug

    Aripiprazole lauroxil

    go.drugbank.com/drugs/DB14185
    Approved

    On July 2nd, a different formulation of aripiprazole lauroxil marketed as Aristada Initio was FDA-approved for immediate initiation of Aristada at any dose. … The patients may receive Aristada Initio in combination with a single 30 mg oral dose of aripiprazole to achieve appropriate levels of aripiprazole more rapidly.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome